| Literature DB >> 27405842 |
Khlifi Latifa1, Sahli Sondess1, Graiet Hajer1, Ben-Hadj-Mohamed Manel1, Khelil Souhir1, Bouzidi Nadia1, Jaballah Abir1, Ferchichi Salima1, Miled Abdelhedi1.
Abstract
Pressure ulcer (PU) remains a common worldwide problem in all health care settings, it is synonymous with suffering. PU is a complex disease that is dependent on a number of interrelated factors. It involves multiple mechanisms such as physiological risk factors, chronic inflammation, oxidant-antioxidant imbalance and proteolytic attack on extracellular matrix by matrix metalloproteinases (MMP). Therefore, we propose that these wounds lead to molecular variations that can be detected by assessing biomarkers. In this study, we aimed to evaluate the major clinical elements and biological scars in Tunisian patients suffering from PU. Consistently, non-healing wound remains a challenging clinical problem. The complex challenges of the wound environment, involving nutrient deficiencies, bacterial infection, as well as the critical role played by inflammatory cells, should be considered because of their negative impact on wound healing. In addition, an imbalance between pro-oxidants and antioxidant systems seems to be more aggravated in patients with PU compared to healthy subjects. Of interest, this study provides further evidence to support a core role of the biological activity of MMP-9 in the pathogenesis of PU and indicates that the MMP9-1562 C/T (rs 3918242) functional polymorphism is associated with protection against this disease.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27405842 PMCID: PMC4942564 DOI: 10.1038/srep29371
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Common pressure ulcer locations.
Figure 2Stages of pressure ulcer.
Figure 3Colorielle classification scale wounds.
Assessment of degree of malnutrition according to analysis of serum albumin level, BMI and indexes in patients suffering from PU.
| Parameters | Albumin (g/l) (27.91 ± 8.15) | BMI (Kg/m2) (20.92 ± 3.29) | NRI (71.83 ± 29.11) | PINI (139.63 ± 342.31; M = 27.36) |
|---|---|---|---|---|
| Degree | ||||
| Normal | 30 < Alb < 35 36.51 ± 4.74 34% | 25 < BMI ≤ 30 32.35 ± 1.31 6% | NRI > 97.5 106.26 ± 7.55 29% | 1 < PINI < 10 4.87 ± 2.97 26% |
| Moderate | 25 < Alb < 30 28.38 ± 1.59 25% | 18.5 < BMI < 25 21.23 ± 1.45 54% (mildly impaired) | 83.5 < NRI < 97.5 90.83 ± 4.01 23% | 11 < PINI < 20 14.87 ± 3.27 22% |
| Severe | Alb < 25 20.35 ± 4.66 41% | 16.5 < BMI < 18.5 17.98 ± 0.41 33% (Moderately) | NRI < 83.5 52.73 ± 20 48% | 21 < PINI < 30 25.8 ± 3.3 13% (Severely) |
| BMI < 16.5 16.38 ± 0.6 7% (Severely) | PINI > 30 281.82 ± 459.73 (M = 89.4) 39% (Risk for death) |
Abbreviations: Albumin (Alb), Body mass index (BMI), Median (M), Nutritional risk index (NRI), Prognostic inflammatory and nutritional index (PINI).
The clinical and laboratory variables of the participants.
| Variables | Patients (n = 100) | Controls (n = 213) | P |
|---|---|---|---|
| Women/Men | 26/74 | 88/125 | 0.001 |
| Age, years | 55.5 ± 20 | 51.5 ± 17 | 0.016 |
| BMI, kg/m2 | 20.92 ± 3.29 | 24.09 ± 3.36 | 0.000 |
| Glucose, mmol/l | 7.04 ± 3.44 | 6.03 ± 2.12 | 0.004 |
| Urea, mmol/l | 6.95 ± 6.13 | 4.68 ± 1.79 | 0.000 |
| Creatinine, μmol/l | 117.86 ± 162.97 (M = 66.5[α1 48.5; α2 96.5]) | 74.98 ± 81.84 (M = 62 [α1 54; α2 75]) | 0.007 |
| Uric acid, μmol/l | 202.68 ± 143.68 | 214.01 ± 75.8 | 0.41 |
| Protide, g/l | 64.33 ± 10.86 | 74.37 ± 6.17 | 0.000 |
| Cholesterol, mmol/l | 3.25 ± 1.2 | 4.67 ± 1.03 | 0.000 |
| Triglyceride, mmol/l | 1.54 ± 0.72 | 1.33 ± 0.81 | 0.048 |
| HDL-C, mmol/l | 0.76 ± 0.46 | 2.01 ± 1.29 | 0.000 |
| LDL-C, mmol/l | 1.38 ± 1.15 | 2.23 ± 1.04 | 0.000 |
| CRP, mg/l | 98.69 ± 76.93 | 6.31 ± 6.25 | 0.000 |
| α1‐acid glycoprotein, g/l | 1.85 ± 0.62 | 1 ± 0.5 | 0.000 |
| Albumin, g/l | 27.91 ± 8.15 | 40.79 ± 8.43 | 0.000 |
| Prealbumin, g/l | 0.13 ± 0.11 | 0.28 ± 0.15 | 0.000 |
| Homocysteine, μmol/l | 27.22 ± 12.50 | 10.46 ± 3.64 | 0.003 |
| TBARS, μmol/l | 0.47 ± 0.31 | 1.11 ± 1 | 0.000 |
| TAS, mmol/l | 1.48 ± 0.72 | 1.76 ± 0.21 | 0.000 |
Abbreviations: Body mass index (BMI), C-reactive protein (CRP), High density lipoprotein cholesterol (HDL-C), Low density lipoprotein cholesterol (LDL-C), Median (M), Thiobarbituric acid reactive substances (TBARS), Total antioxidant status (TAS).
Figure 4Representative gelatin zymograms of serum samples with MMP-9 forms.
Figure 5MMP9-1562C/T (rs3918242) genotyping by PCR-restriction fragment length polymorphism.
Distribution of MMP9-1562C/T alleles and genotypes in patients with PU and control groups.
| Patients, n (%) (n = 100) | Controls, n (%) (n = 213) | P-value | OR | 95% CI | |
|---|---|---|---|---|---|
| Allele T | 21 (10.5%) | 75 (17.61%) | 0.55 | [0.33–0.92] | |
| CC | 79 (79%) | 142 (67%) | 1 | ||
| CT | 21 (21%) | 67 (31.44%) | 0.58 | [0.33–1.02] | |
| TT | 0 | 4 (1.9%) | – | – | |
| CT + TT | 21 (21%) | 71 (33%) | 0.025 | 0.53 | [0.3–0.93] |
Abbreviations: Confidence interval (CI), Odds ratio (OR).